Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells. It has developed CAR-T cell therapy extracted from patient's blood cells to target cancerous cells. The product pipeline includes IMN-003A, IMN-001, and IMN-002 for leukemias and lymphomas.
← All startups
Immuneel
Series BDeveloper of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells. It has developed CAR-T cell therapy extracted from patient's blood cells to target cancerous cells. The product pipeline includes IMN-003A, IMN-001, and IMN-002 for leukemias and lymphomas.
About
Institutional investors
Kotak Mahindra BankTaiba HealthcareEight Roads VenturesTrue North Venture PartnersF-Prime CapitalKhosla VenturesBeta Operators FundGLENTECApollo HospitalsTrue NorthSister Fund RvaStempeutics
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Backed by funds in our directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.